Transgenic expression of osteoactivin in the liver attenuates hepatic fibrosis in rats

Biochem Biophys Res Commun. 2007 May 11;356(3):610-5. doi: 10.1016/j.bbrc.2007.03.035. Epub 2007 Mar 15.

Abstract

The role of osteoactivin (OA) in liver fibrogenesis remains unclear. After feeding wild-type (WT) and OA transgenic (OA-Tg) rats a choline-deficient, L-amino acid-defined (CDAA) diet for 12 weeks, we evaluated liver fibrosis. Hepatic fibrosis and expression of alpha-smooth muscle actin protein in OA-Tg rats were reduced in comparison to WT rats. Our examination of the expression of 31,100 genes by microarray analysis identified 177 and 256 genes that were upregulated and downregulated, respectively, by at least twofold in OA-Tg rat livers in comparison to WT rat livers. Of these genes, we confirmed a significant downregulation in the expression levels of tissue inhibitor of metalloproteinase-1 and -2, type I collagen, and platelet-derived growth factor receptor-alpha and -beta in the livers of OA-Tg rats. These results indicate that transgenic OA expression attenuates the development of hepatic fibrosis in association with the suppression of specific genes involved in its pathogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Genetically Modified
  • Choline Deficiency / metabolism
  • Gene Expression Profiling
  • Genetic Therapy
  • Liver / metabolism*
  • Liver Cirrhosis / therapy*
  • Membrane Glycoproteins / biosynthesis*
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Platelet-Derived Growth Factor alpha / biosynthesis
  • Tissue Inhibitor of Metalloproteinase-1 / biosynthesis

Substances

  • Gpnmb protein, rat
  • Membrane Glycoproteins
  • Tissue Inhibitor of Metalloproteinase-1
  • Receptor, Platelet-Derived Growth Factor alpha